Current stock page

Financial Data

NRIX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

NRIXNurix Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$15.48−$0.12 (−0.77%)

Latest quote

  • Momentum
    50
  • Value
    94
  • Quality
    78
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-08-312026-05-312026-02-282025-11-302025-08-312025-05-312025-02-282024-11-30
Revenue$673.06M$9.04M$6.25M$13.58M$7.89M$44.06M$18.45M$13.28M
Gross Profit$670.93M$5.19M-$77.89M$8.95M$2.89M-$34.04M-$51.21M-$53.94M
Operating Income$559.45M-$94.2M-$92.5M-$83.1M-$91.39M-$48.32M-$62.86M-$64.66M
Net Income$549.81M-$89.54M-$87.17M-$78.22M-$86.42M-$43.46M-$56.35M-$58.55M
EPS$4.93-$0.81-$0.79-$0.82-$1.03-$0.52-$0.67-$0.75
Cash flow statement
8 periods
Metric2026-08-312026-05-312026-02-282025-11-302025-08-312025-05-312025-02-282024-11-30
Operating Cash Flow$615.63M-$96.57M-$71.91M-$67.83M-$57.39M-$63.16M-$61.09M-$48.75M
Capital Expenditure-$1.39M-$1.94M-$1.05M-$5.13M-$2.71M-$2.68M-$3.49M-$2.11M
Free Cash Flow$614.24M-$98.51M-$72.96M-$72.96M-$60.1M-$65.84M-$64.57M-$50.86M
Net Cash Provided By Operating Activities$615.63M-$96.57M-$71.91M-$67.83M-$57.39M-$63.16M-$61.09M-$48.75M
Balance sheet
8 periods
Metric2026-08-312026-05-312026-02-282025-11-302025-08-312025-05-312025-02-282024-11-30
Total Assets$1.2B$535.54M$636.13M$688.14M$522.47M$591.56M$615.04M$669.34M
Total Debt$65.33M$58.14M$58.66M$55.73M$56.49M$51.93M$26.62M$28.3M
Cash And Cash Equivalents$720.24M$67.69M$71.2M$246.96M$78.44M$84.26M$75.92M$110M
Total Liabilities$226.99M$132.91M$155.24M$149.39M$150.22M$143.95M$134.13M$142.35M
Total Stockholders Equity$968.31M$402.63M$480.89M$538.75M$372.25M$447.6M$480.92M$526.99M
Key financial metrics
8 periods
Metric2026-08-312026-05-312026-02-282025-11-302025-08-312025-05-312025-02-282024-11-30
P/E ratio8.72———————
P/B ratio2.656.813.573.152.462.471.612.91
P/S ratio2.46———————
Debt To Equity0.070.140.120.10.150.120.060.05
Free Cash Flow Yield14.39%-11.10%-15.83%-15.50%-26.41%-20.42%-26.05%-11.86%
Financial ratios
8 periods
Metric2026-08-312026-05-312026-02-282025-11-302025-08-312025-05-312025-02-282024-11-30
P/E ratio8.72———————
P/B ratio2.656.813.573.152.462.471.612.91
P/S ratio2.46———————
Return On Equity30.45%-84.78%-61.40%-49.09%-65.76%-46.32%-43.33%-36.73%
Debt To Equity0.070.140.120.10.150.120.060.05

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe6.17x
Pb1.78x
Revenue Growth Yoy8426.27%
EPS Growth Yoy578.64%
Gross Margin86.50%
Operating Margin41.27%
ROE49.34%
ROIC25.95%
Debt To Equity0.07
FCF Yield21.87%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$15.48
Volume1.39M
RSI (14)26.77
MACD-2.48
MACD signal-1.61
MACD histogram-0.87
ADX (14)35.95
SMA (50)$23.27
SMA (200)$20.13
ATR (14)$1.54
Historical volatility (annualized)145.46%
Volume (20-day average)3.9M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score40/100
Beta1.06
Annual volatility67.30%
Max Drawdown-46.60%
Sharpe Ratio0.64
VaR (95%, 1-day)-4.78%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NRIX Financial Data FAQ

What is Nurix Therapeutics, Inc.'s revenue?

Nurix Therapeutics, Inc.'s revenue is one of the core financial data points for NRIX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Nurix Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Nurix Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NRIX's EPS?

NRIX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Nurix Therapeutics, Inc.'s net income?

Nurix Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Nurix Therapeutics, Inc. generate?

Free cash flow shows how much cash Nurix Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Nurix Therapeutics, Inc. have?

Cash and debt help frame NRIX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.